Analyst
Goldman Sachs
Equibles does not estimate personal net worth.
Asad Ader is recorded as Analyst at Goldman Sachs. Asad Ader has spoken on 2 earnings calls across 2 companies, most recently for Merck & Co., Inc. on August 4, 2026. Those appearances were for Merck & Co., Inc. (MRK) and Johnson & Johnson (JNJ). The companies whose calls Asad Ader spoke on are classified in the Healthcare sector.
“Maybe for Dean, on the PD-1 VEGF bi-specific program, just any updates on how the pace of that development is progressing and how you're thinking about any potential read-across from Summit's Harmony 3 data coming up and any update on where you are with potential combination trials with the PD-1 VEGF and your ADC…”
“Joaquin, maybe just a big-picture question for you. You're entering this year in a clear position of strength following what's been one of the best performance years for the stock in about 20 years.”
Goldman Sachs
Analyst
Transcript header (unverified)
Drug Manufacturers - General · Healthcare
Drug Manufacturers - General · Healthcare
